ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Significant Increase in Short Interest

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 628,000 shares, a growth of 148.2% from the November 30th total of 253,000 shares. Based on an average trading volume of 246,500 shares, the days-to-cover ratio is currently 2.5 days. Approximately 5.6% of the company’s shares are short sold.

ABVC BioPharma Trading Up 9.6 %

ABVC BioPharma stock opened at $0.56 on Friday. The company has a 50-day moving average price of $0.55 and a 200 day moving average price of $0.65. ABVC BioPharma has a 12-month low of $0.41 and a 12-month high of $2.45. The stock has a market cap of $7.25 million, a P/E ratio of -0.65 and a beta of 0.72.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.